Alphamab's HER2 bispecific antibody to enter clinic in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) will begin in 3Q18 the dose-escalation portion of a Chinese Phase I trial evaluating KN026 to treat HER2-positive locally advanced and metastatic solid tumors in patients who failed previous treatments. Data are expected in 4Q19.

The study will enroll about 15-20 patients in the dose-escalation portion, plus about 40 patients in an expansion portion. The primary endpoint is safety. Secondary endpoints will assess pharmacokinetics, anti-KN026 antibodies and efficacy...